Ascendis Pharma A/S's latest marketcap:
As of 06/03/2026, Ascendis Pharma A/S's market capitalization has reached $13.47 B. According to our data, Ascendis Pharma A/S is the 1743th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 13.47 B |
| Revenue (ttm) | 998.25 M |
| Net Income (ttm) | 571.81 M |
| Shares Out | 62.11 M |
| EPS (ttm) | 9.26 |
| Forward PE | 49.69 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/07/2026 |
Ascendis Pharma A/S's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 06/03/2026 | $13.47 B | 4.32% | 1743 |
| 12/31/2025 | $13.03 B | 64.48% | 1770 |
| 12/31/2024 | $7.92 B | 9.08% | 2090 |
| 12/29/2023 | $7.26 B | 4.27% | 2124 |
| 12/30/2022 | $6.96 B | -3.83% | 2035 |
| 12/31/2021 | $7.24 B | -17.63% | 2371 |
| 12/31/2020 | $8.79 B | 32.38% | 1798 |
| 12/31/2019 | $6.64 B | 152.21% | 1900 |
| 12/31/2018 | $2.63 B | 80.76% | 3338 |
| 12/29/2017 | $1.46 B | 185.54% | 5642 |
Company Profile
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company dedicated to developing innovative therapies using its proprietary TransCon technology. The company operates globally, with a focus on addressing unmet medical needs in Denmark, Europe, North America, and other international markets.
Key Products
- SKYTROFA – A treatment for pediatric patients with growth hormone deficiency.
- YORVIPATH – A once-daily subcutaneous injection designed for adults with chronic hypoparathyroidism.
Pipeline & Research Focus
The company is actively advancing its pipeline, which includes:
- Three independent endocrinology rare disease product candidates in clinical development.
- Oncology therapeutic candidates in various stages of research.
Company Background
Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Frequently Asked Questions
-
What is Ascendis Pharma A/S's (ASND) current market cap?As of 06/03/2026, Ascendis Pharma A/S (including the parent company, if applicable) has an estimated market capitalization of $13.47 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Ascendis Pharma A/S (ASND) rank globally by market cap?Ascendis Pharma A/S global market capitalization ranking is approximately 1743 as of 06/03/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.